SehaMed Partners with New Day Diagnostics
We are excited to announce our partnership with New Day Diagnostics to launch the ColoHealth™️ Blood Test for Colorectal Cancer Screening in the Middle East.
Bristol, UK & Knoxville, TN – July 18, 2025 SehaMed Global Ltd (“SehaMed”), the Bristol based MedTech platform connecting manufacturers, distributors, and hospitals worldwide, today announced a strategic distribution agreement with New Day Diagnostics, LLC (“New Day Diagnostics”) of Knoxville, Tennessee, to bring ColoHealth™, the first FDA approved blood test for early detection of colorectal cancer, to populations across Saudi Arabia, the United Arab Emirates, and beyond.
Addressing a Critical Healthcare Need
Colorectal cancer (CRC) is one of the leading cancer burdens in the Middle East. In Saudi Arabia, CRC accounted for 14.6% of all cancer cases and 1.48% of cancer related deaths in 2020, making it the second most common cancer overall. In the UAE, the age standardized incidence rates reached 13 per 100,000 for males and 12.8 per 100,000 for females in 2021. Early detection is crucial. Screening programs can reduce mortality by up to 60%, yet participation rates remain low due to cultural barriers and resource constraints.
About the Partnership
Under the terms of the agreement, SehaMed will leverage its platform and network of qualified distributors across the Gulf Cooperation Council (GCC) to introduce ColoHealth. New Day Diagnostics’ Vice President, Rick Jones, commented, “Partnering with SehaMed accelerates our mission to make early CRC screening accessible globally. The Middle East represents a vital region where innovative, non-invasive diagnostics can transform patient outcomes.”
Anne Hegmann-Weston, Director at SehaMed, added, “We are excited to collaborate with New Day Diagnostics to offer ColoHealth to clinicians and patients in Saudi Arabia, UAE, and neighbouring markets. This agreement underscores SehaMed’s commitment to improving patient care by connecting groundbreaking US diagnostics with distributors and healthcare providers in the Middle East.”
ColoHealth™: A Game Changing Diagnostic
ColoHealth™ is an innovative blood test that detects aberrantly methylated Septin 9, a biomarker associated with colorectal cancer. Designed as a convenient alternative to traditional screening methods, ColoHealth™ improves screening compliance in asymptomatic individuals, helping detect CRC at earlier stages. This leads to better patient outcomes and reduced mortality.
About SehaMed Global Ltd
Founded in 2017 and headquartered in Bristol, England, SehaMed operates the world’s first MedTech platform connecting manufacturers, distributors, and hospitals to streamline international market access. Acting as both a platform operator and an exclusive agent for select and transformative technologies, SehaMed delivers end-to-end market management solutions that drive rapid growth and lasting partnerships across Europe, the Middle East, Latin America, Asia, and beyond.
About New Day Diagnostics, LLC
New Day Diagnostics, established through the merger of EDP Biotech and New Day Diagnostics in 2023, is a CLIA certified laboratory and ISO13485-2016 diagnostics developer based in Knoxville, Tennessee. Led by CEO Eric Mayer, the company specializes in oncology, digestive disease, and clinical research with a mission to deliver accessible, lifesaving diagnostics from concept to market.